

SFB 876 Providing Information by Resource-**Constrained Data Analysis**





Project C1 Feature selection in high dimensional data for risk prognosis in oncology

Prof. Dr. Alexander Schramm, Prof. Dr. Sven Rahmann

New Dimension of Data Volume: Whole genome & nanopore sequencing

Features are derived from molecular probes or sequences (reads).



New Sequencing Technology: MinION nanopore

- Small portable device (size of a USB stick)
- Analysis on a laptop
- Large lab infrastructure no longer necessary
- Democratisation of access to sequencing
- One flow cell can generate 10–20 Gb of DNA sequence data. Ultra-long reads are possible (>100 Kbp) Disadvantage: high error rates (10–15%)



UNIVERSITÄT

DUISBURG ESSEN

Offen im Denken

Goals:

- Real-time algorithms that convert the changes in ion currents at the nanopores immediately into the corresponding DNA sequence
- Prognostic biomarkers from liquid biopsies and nanopore sequencing
- Collaboration about detection and extraction of tumor vesicles

Source: http://www.bio-itworld.com/uploadedImages/Bio-IT_World/Top_Headlines/ 2014/12-Dec/MinION%20close%20up.jpg



Efficient Whole Genome Analysis with DNA *k*-mers

Use genomewide-unique *k*-mers

 $(k \in \{21, 23, 25, \dots\})$ for

- single nucleotide variant (SNV) discovery
- copy number variants (CNVs)
- structural variants (translocations, fusions)
- methylation analysis from WGBS data
- gene expression analysis from RNA-seq

Key Data Structure: Efficient DNA *k*-mer Key-Value Store

Challenge: small hash table and fast look-ups **Speed bottleneck:** cache misses during memory look-ups **New proposal:** 3-way bucketed Cuckoo hashing with quotienting



Gene Knock Outs by **CRISPR / Cas9 Genome Editing**

- Cultivation of human cancer cells in vitro (2D/3D)
- Transfection with Cas9 ribonucleoproteins or lentiviral transduction
- Double strand break generation by Cas9 to create a gene knock-out
- The inactive nuclease Cas9 complex with

- Feature generation from whole genomes on a standard laptop:
- Output only unique k-mers that deviate from expected count: new *k*-mers, lost *k*-mers, surprising copy number, ...
- Project deviant k-mers to biological entities (regions, genes, transcripts, pathways)
- Detect enrichment of deviant k-mers and deviant biological entities in tumour samples

Feature reduction:

- Aggregation: Variant \rightarrow Gene \rightarrow Pathway
- Clustering of similar features with graph-based methods



Maximal fill rates of hash table for different numbers of hash functions (H: 2 or 3), bucket sizes (x-axis, 1–15) and bounds on random walk length during insertion (W: 100, 500, 1000, 5000, 10000). Look-up needs H cache misses in the worst case.

three activation domains activates transcription (CRISPR SAM).



- Fluorescence activated cell sorting (FACS)
- Quantitative Polymerase chain reaction (qPCR)
- MinION RNA sequencing

Analysis of Ion Current Data

Establishment of the technology and preliminary experiments on microbiomes:



Biological Target Validation

Validation of CRISPR / Cas9 based knock-out and overexpression by Western Blot analysis



Computational challenge: Lightweight conversion of ion current signal to DNA sequence

Signal segmentation: Fused LASSO; given signal $y = (y_i)$,

min
$$f(x) := \sum_{i=1}^{n} (x_i - y_i)^2 + \lambda \cdot \sum_{i=1}^{n-1} |x_{i+1} - x_i|.$$

- Discretisation of signal levels; new efficient algorithms for discretised fused LASSO, where x_i must be from a finite known level set *L*.
- Learn mapping between k-mers of level set L to (modified) DNA sequence

Alternative approach:

- Work with *k*-mers of discretised signal space *L* directly (richer representation)
- \blacktriangleright Discover variants as for WGS analysis in L^k -space

westdeutsches

tumorzentrum

3D culture reveals decreased spheroid formation ability and invasiveness upon PRKCI knock-out, while over-expression of PRKCI increases the invasiveness of SH-EP cells (neuroblastoma cell line).



Chair of Genome Informatics Institute of Human Genetics University Hospital Essen University of Duisburg-Essen



Molecular Oncology Internal Medicine/Cancer Research Unit University Hospital Essen University of Duisburg-Essen